Mymetics (Mymetics) Cash And Cash Equivalents : $0.07 Mil (As of Sep. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Mymetics Cash And Cash Equivalents?

Mymetics's quarterly cash and cash equivalents increased from Mar. 2023 ($0.36 Mil) to Jun. 2023 ($0.44 Mil) but then stayed the same from Jun. 2023 ($0.44 Mil) to Sep. 2023 ($0.07 Mil).

Mymetics's annual cash and cash equivalents declined from Dec. 2020 ($1.32 Mil) to Dec. 2021 ($0.65 Mil) and declined from Dec. 2021 ($0.65 Mil) to Dec. 2022 ($0.33 Mil).

Mymetics Cash And Cash Equivalents Historical Data

The historical data trend for Mymetics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mymetics Cash And Cash Equivalents Chart

Mymetics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.55

0.76

1.32

0.65

0.33

Mymetics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.40	0.33	0.36	0.44	0.07

Mymetics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Mymetics (OTCPK:MYMX) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Mymetics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Mymetics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Mymetics (Mymetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mymetics Corp (OTCPK:MYMX) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/o Mymetics SA, Route de la Corniche 4, Biopole Center, Epalinges, CHE, CH-1066

Website

https://www.mymetics.com

Mymetics Corp is a vaccine company and is focused on the research and development of next-generation vaccines for infectious and life-disabling diseases. Its vaccine candidates in the pipeline include HIV-1/AIDS, malaria, and Covid-19, and intranasal influenza, RSV, Chikungunyaand HSV vaccine candidate programs.

Executives

Marcel B. Ruegg	director	C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Kempers Ronald Hugo Gerard	officer: President, CEO, CFO	ES GRANDS CHAMPS 12, DULLY V8 1195
Christopher S Henney	director	10505 ROSELLE STREET, SAN DIEGO CA 92121
Grant Pickering	director, officer: President and CEO	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Ulrich Burkhard	director	C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Jacques Francois Martin	officer: CEO	40 QUAI FULCHIRON, LYON I0 69005
Antonius Johannes Stegmann	officer: CSO	KONINGIN EMMAPLANTSOEN 6, RIJNSBURG P7 2231TZ
Ernest M Stern	director	815 CONNECTICUT AVE, NW, SUITE 500, SEYFARTH SHAW LLP, WASHINGTON DC 20006
Thomas Staehelin	director	POSTFACH 2879, FROMER, SCHULTHEISS & STAEHELIN, BASEL V8 CH-4002
Sylvain Fleury	officer: CSO	CHEMIN DE VERDONNET 9, LAUSANNE V8 1010
Round Enterprises, Ltd.	10 percent owner	C/O BACHMANN TRUST COMPANY LIMITED, FRANCES HOUSE, SIR WILLIAM PLACE, ST. PETER PORT X0 GY1 4EA
Mfc Bancorp Ltd	10 percent owner	ROOM 2103 SHANGHAI MART TOWER, 2299 YAN AN ROAD WEST, CHANGNING DISTRICT, SHANGHAI F4 200336
Christian Rochet	director, officer: CEO	14, RUE DE LA COLOMBIERE, NYON V8 1260
Robert Zimmer	director, officer: vp corp development
Ernst Lubke	director, officer: CFO	39, ROUTE D'ARZIER, ARZIER V8 CH-1273